SG11202005251VA - Formulations of dengue virus vaccine compositions - Google Patents
Formulations of dengue virus vaccine compositionsInfo
- Publication number
- SG11202005251VA SG11202005251VA SG11202005251VA SG11202005251VA SG11202005251VA SG 11202005251V A SG11202005251V A SG 11202005251VA SG 11202005251V A SG11202005251V A SG 11202005251VA SG 11202005251V A SG11202005251V A SG 11202005251VA SG 11202005251V A SG11202005251V A SG 11202005251VA
- Authority
- SG
- Singapore
- Prior art keywords
- formulations
- dengue virus
- vaccine compositions
- virus vaccine
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 2
- 229940023605 dengue virus vaccine Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762595842P | 2017-12-07 | 2017-12-07 | |
PCT/US2018/063541 WO2019112921A1 (en) | 2017-12-07 | 2018-12-03 | Formulations of dengue virus vaccine compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202005251VA true SG11202005251VA (en) | 2020-07-29 |
Family
ID=66750326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202005251VA SG11202005251VA (en) | 2017-12-07 | 2018-12-03 | Formulations of dengue virus vaccine compositions |
Country Status (23)
Country | Link |
---|---|
US (3) | US20200390877A1 (en) |
EP (1) | EP3720487A1 (en) |
JP (1) | JP7042341B2 (en) |
KR (1) | KR102494651B1 (en) |
CN (2) | CN111447947B (en) |
AU (1) | AU2018381213B2 (en) |
BR (1) | BR112020011205A8 (en) |
CA (1) | CA3083772A1 (en) |
CL (1) | CL2020001463A1 (en) |
CO (1) | CO2020006836A2 (en) |
CR (1) | CR20200242A (en) |
DO (1) | DOP2020000098A (en) |
EA (1) | EA202091398A1 (en) |
EC (1) | ECSP20032084A (en) |
GE (1) | GEP20237539B (en) |
IL (1) | IL274897B1 (en) |
JO (1) | JOP20200140A1 (en) |
MA (1) | MA51060A (en) |
MX (1) | MX2020005857A (en) |
NI (1) | NI202000039A (en) |
PE (1) | PE20210654A1 (en) |
SG (1) | SG11202005251VA (en) |
WO (1) | WO2019112921A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020011205A8 (en) | 2017-12-07 | 2023-02-07 | Merck Sharp & Dohme | FORMULATIONS OF VACCINE COMPOSITIONS AGAINST DENGUE VIRUS |
WO2022094816A1 (en) * | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Solid formulation |
EP4419205A1 (en) * | 2021-10-20 | 2024-08-28 | Solventum Intellectual Properties Company | Phosphate and arginine containing compositions and the delivery of such compositions for virulence suppression |
WO2024073362A2 (en) * | 2022-09-29 | 2024-04-04 | Board Of Regents, The University Of Texas System | Methods and compositions for transport, storage, and delivery of nucleic acids and other molecules |
EP4356925A3 (en) | 2022-10-18 | 2024-05-01 | Takeda Vaccines, Inc. | Dengue vaccine formulation |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69233566T2 (en) | 1991-09-19 | 2006-08-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric and / or growth-inhibited flaviviruses |
FR2702660B1 (en) * | 1993-03-17 | 1995-05-24 | Karl Simpson | Stabilized therapeutic compositions and process for their preparation. |
US6254873B1 (en) | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
US6190859B1 (en) | 1995-04-17 | 2001-02-20 | The United States Of America As Represented By The Secretary Of The Army | Method and kit for detection of dengue virus |
US6432411B1 (en) | 1999-07-13 | 2002-08-13 | Hawaii Biotechnology Group | Recombinant envelope vaccine against flavivirus infection |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
BR122019026154B8 (en) | 2001-05-22 | 2021-07-27 | The Government Of The Us Secretary Department Of Health And Human Services | attenuated dengue virus, pharmaceutical compositions comprising said virus, kit, tetravalent, live attenuated and inactivated dengue virus vaccines, and methods for preparing a dengue virus and a pharmaceutical composition |
WO2003102166A2 (en) * | 2002-02-26 | 2003-12-11 | Maxygen, Inc. | Novel flavivirus antigens |
AU2003224810B2 (en) * | 2002-03-26 | 2006-08-31 | Immunex Corporation | Methods of using Flt3-ligand in immunization protocols |
BRPI0309631B1 (en) | 2002-05-03 | 2021-07-20 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | TETRAVALENT IMMUNOGENIC COMPOSITION INCLUDING ATTENUED DENGUE VIRUS AND TETRAVALENT VACCINE INCLUDING SUCH COMPOSITION |
US20050123550A1 (en) * | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
CN101128216A (en) * | 2005-01-05 | 2008-02-20 | 费城健康和教育公司 | Delivery vehicles, bioactive substances and viral vaccines |
CN101222936A (en) | 2005-06-24 | 2008-07-16 | 英特威国际有限公司 | Inactivated chimeric and related methods of use |
BRPI0616879A2 (en) * | 2005-10-04 | 2011-07-05 | Alk Abello As | solid vaccine formulation |
EP2324850A1 (en) | 2005-10-04 | 2011-05-25 | Alk-Abelló A/S | Solid vaccine formulation |
LT2589602T (en) | 2006-08-15 | 2016-10-10 | The Government Of The U.S.A., As Repr. By The Secretary, Dept. Of Health & Human Services, The Nat. Inst. Of Health | Development of dengue virus vaccine components |
US20080275030A1 (en) * | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
CA2720570C (en) | 2007-04-06 | 2022-10-04 | Inviragen, Inc. | Methods and compositions for live, attenuated dengue viruses |
EP2143440A1 (en) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Stabilising agent and vaccine composition comprising one or several attenuated living flavivirus |
JP5548207B2 (en) * | 2008-09-24 | 2014-07-16 | メディミューン,エルエルシー | Virus purification method |
US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
JP2012520084A (en) | 2009-03-13 | 2012-09-06 | レンチゲン コーポレイション | Non-integrated retroviral vector vaccine |
GB201002419D0 (en) * | 2010-02-12 | 2010-03-31 | Isis Innovation | Stable live vaccine formulations |
SG10201801947YA (en) | 2010-10-29 | 2018-04-27 | Merck Sharp & Dohme | Recombinant subunit dengue virus vaccine |
JP2014515367A (en) | 2011-05-26 | 2014-06-30 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Inactivated dengue virus vaccine |
SI2811981T1 (en) * | 2012-02-07 | 2019-08-30 | Infectious Disease Research Institute | Improved adjuvant formulations comprising tlr4 agonists and methods of using the same |
US9314519B2 (en) * | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
US9974850B2 (en) * | 2013-01-25 | 2018-05-22 | Board Of Regents, The University Of Texas System | Immunogenic compositions and uses thereof |
US9254332B2 (en) * | 2013-03-15 | 2016-02-09 | Arecor Limited | Stable aqueous formulations of adenovirus vectors |
SG11201510266SA (en) | 2013-06-21 | 2016-01-28 | Merck Sharp & Dohme | Dengue virus vaccine compositions and methods of use thereof |
US9782470B2 (en) | 2013-10-16 | 2017-10-10 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
CN105636609A (en) | 2013-10-25 | 2016-06-01 | 白血球保健股份有限公司 | A novel method for the production of stabile vaccines |
WO2015093452A1 (en) | 2013-12-16 | 2015-06-25 | 武田薬品工業株式会社 | Microneedle |
EP3089754B1 (en) * | 2013-12-31 | 2021-04-21 | Infectious Disease Research Institute | Single vial vaccine formulations |
WO2015130157A1 (en) | 2014-02-28 | 2015-09-03 | Universiti Malaya | Enhancement of dengue virus production |
BR112017013270A2 (en) | 2014-12-22 | 2018-03-06 | Merck Sharp & Dohme | "dengue virus vaccine composition, methods for inducing a dengue immune response, reducing the likelihood of dengue infection, or preventing or alleviating dengue symptoms, and use of a dengue virus vaccine composition." |
CN107949636B (en) * | 2015-06-04 | 2021-11-09 | 香港大学 | Live attenuated viruses and methods of production and use |
US20180296663A1 (en) * | 2015-06-17 | 2018-10-18 | Curevac Ag | Vaccine composition |
US10004795B2 (en) | 2015-09-08 | 2018-06-26 | Fundacao Butantan | Process for preparing an attenuated tetravalent dengue vaccine |
KR20180041761A (en) * | 2015-09-30 | 2018-04-24 | 파나세아 바이오테크 리미티드 | Stable attenuated recombinant dengue live vaccine |
WO2017109698A1 (en) | 2015-12-22 | 2017-06-29 | Glaxosmithkline Biologicals Sa | Immunogenic formulation |
CA3018216A1 (en) | 2016-03-25 | 2017-09-28 | Visterra, Inc. | Formulations of antibody molecules to dengue virus |
CA3020484A1 (en) * | 2016-04-13 | 2017-10-19 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
TWI766876B (en) | 2016-08-03 | 2022-06-11 | 美商武田疫苗股份有限公司 | Compositions and methods for stabilizing flaviviruses with improved formulations |
EP3532093A1 (en) | 2016-09-19 | 2019-09-04 | Vaxess Technologies, Inc. | Vaccine formulations with increased stability |
WO2018183426A1 (en) | 2017-03-30 | 2018-10-04 | Merck Sharp & Dohme Corp. | Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids |
KR20200088326A (en) | 2017-10-16 | 2020-07-22 | 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 | In particular, a stable vaccine composition comprising a live attenuated recombinant flavivirus and a method for manufacturing the same |
BR112020011205A8 (en) * | 2017-12-07 | 2023-02-07 | Merck Sharp & Dohme | FORMULATIONS OF VACCINE COMPOSITIONS AGAINST DENGUE VIRUS |
-
2018
- 2018-12-03 BR BR112020011205A patent/BR112020011205A8/en unknown
- 2018-12-03 EP EP18887100.8A patent/EP3720487A1/en active Pending
- 2018-12-03 MA MA051060A patent/MA51060A/en unknown
- 2018-12-03 JP JP2020530648A patent/JP7042341B2/en active Active
- 2018-12-03 IL IL274897A patent/IL274897B1/en unknown
- 2018-12-03 AU AU2018381213A patent/AU2018381213B2/en active Active
- 2018-12-03 CN CN201880079043.XA patent/CN111447947B/en active Active
- 2018-12-03 JO JOP/2020/0140A patent/JOP20200140A1/en unknown
- 2018-12-03 PE PE2020000684A patent/PE20210654A1/en unknown
- 2018-12-03 CR CR20200242A patent/CR20200242A/en unknown
- 2018-12-03 US US16/769,837 patent/US20200390877A1/en not_active Abandoned
- 2018-12-03 SG SG11202005251VA patent/SG11202005251VA/en unknown
- 2018-12-03 CA CA3083772A patent/CA3083772A1/en active Pending
- 2018-12-03 KR KR1020207019204A patent/KR102494651B1/en active IP Right Grant
- 2018-12-03 EA EA202091398A patent/EA202091398A1/en unknown
- 2018-12-03 CN CN202311806711.3A patent/CN117752780A/en active Pending
- 2018-12-03 GE GEAP201815384A patent/GEP20237539B/en unknown
- 2018-12-03 WO PCT/US2018/063541 patent/WO2019112921A1/en active Application Filing
- 2018-12-03 MX MX2020005857A patent/MX2020005857A/en unknown
-
2020
- 2020-05-29 DO DO2020000098A patent/DOP2020000098A/en unknown
- 2020-06-01 NI NI202000039A patent/NI202000039A/en unknown
- 2020-06-01 CL CL2020001463A patent/CL2020001463A1/en unknown
- 2020-06-02 CO CONC2020/0006836A patent/CO2020006836A2/en unknown
- 2020-06-12 EC ECSENADI202032084A patent/ECSP20032084A/en unknown
-
2022
- 2022-07-26 US US17/815,037 patent/US11883480B2/en active Active
-
2023
- 2023-12-06 US US18/530,421 patent/US20240131144A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3083772A1 (en) | 2019-06-13 |
GEP20237539B (en) | 2023-09-11 |
CL2020001463A1 (en) | 2020-09-25 |
KR20200096272A (en) | 2020-08-11 |
WO2019112921A1 (en) | 2019-06-13 |
EP3720487A1 (en) | 2020-10-14 |
IL274897B1 (en) | 2024-11-01 |
NI202000039A (en) | 2020-09-24 |
AU2018381213A1 (en) | 2020-06-11 |
KR102494651B1 (en) | 2023-01-31 |
US20200390877A1 (en) | 2020-12-17 |
IL274897A (en) | 2020-07-30 |
JP2021505588A (en) | 2021-02-18 |
BR112020011205A8 (en) | 2023-02-07 |
US11883480B2 (en) | 2024-01-30 |
ECSP20032084A (en) | 2020-08-31 |
AU2018381213B2 (en) | 2022-03-17 |
BR112020011205A2 (en) | 2020-11-17 |
CN111447947B (en) | 2024-01-12 |
JP7042341B2 (en) | 2022-03-25 |
CR20200242A (en) | 2020-07-17 |
US20230061673A1 (en) | 2023-03-02 |
MA51060A (en) | 2021-03-17 |
CO2020006836A2 (en) | 2020-06-19 |
JOP20200140A1 (en) | 2022-10-30 |
DOP2020000098A (en) | 2020-08-31 |
US20240131144A1 (en) | 2024-04-25 |
CN117752780A (en) | 2024-03-26 |
EA202091398A1 (en) | 2020-09-01 |
PE20210654A1 (en) | 2021-03-31 |
CN111447947A (en) | 2020-07-24 |
MX2020005857A (en) | 2020-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250136A1 (en) | Vaccine compositions having improved stability and immunogenicity | |
ZA201801035B (en) | Vaccine compositions | |
IL274897A (en) | Formulations of dengue virus vaccine compositions | |
SG11201701256RA (en) | Vaccine compositions against dengue virus diseases | |
ZA201904505B (en) | Universal influenza vaccine compositions | |
IL263574A (en) | Calr and jak2 vaccine compositions | |
IL280332A (en) | Composition containing influenza vaccine | |
GB201801566D0 (en) | Methods and compositions for nanormulsion vaccine formulations | |
IL272857A (en) | Formulations of copanlisib | |
ZA201801496B (en) | Vlp stabilized vaccine compositions | |
EP3484511A4 (en) | Vaccine compositions for treatment of zika virus | |
SG11202009147UA (en) | Vaccine compositions | |
HK1255379A1 (en) | Hepatitis c virus immunogenic compositions and methods of use thereof | |
EP3305328A4 (en) | Non-gelatin vaccine protectant composition and live attenuated influenza vaccine | |
GB2562241B (en) | Vaccine compositions | |
SG11201704942QA (en) | Dengue virus vaccine compositions and methods of use thereof | |
ZA201807932B (en) | Physiologically balanced injectable formulations of fosnetupitant | |
GB201703529D0 (en) | Vaccine composition | |
GB201718251D0 (en) | Vaccine Compositions | |
PT3678644T (en) | Formulations of copanlisib | |
GB2564901B (en) | Vaccine compositions | |
GB201906072D0 (en) | Vaccine compositions | |
GB201809541D0 (en) | Vaccine compositions | |
GB201805393D0 (en) | Vaccine compositions | |
GB201712498D0 (en) | Methods of producting vaccine compositions |